JP2024502178A5 - - Google Patents

Info

Publication number
JP2024502178A5
JP2024502178A5 JP2023541702A JP2023541702A JP2024502178A5 JP 2024502178 A5 JP2024502178 A5 JP 2024502178A5 JP 2023541702 A JP2023541702 A JP 2023541702A JP 2023541702 A JP2023541702 A JP 2023541702A JP 2024502178 A5 JP2024502178 A5 JP 2024502178A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
group
acceptable salt
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502178A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/050038 external-priority patent/WO2022150911A1/en
Publication of JP2024502178A publication Critical patent/JP2024502178A/ja
Publication of JP2024502178A5 publication Critical patent/JP2024502178A5/ja
Pending legal-status Critical Current

Links

JP2023541702A 2021-01-13 2022-01-12 Sgk-1を阻害するためのピラゾロ[3,4-d]ピリミジン-6-イル-スルホンアミド誘導体 Pending JP2024502178A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163136782P 2021-01-13 2021-01-13
US63/136,782 2021-01-13
US202163262040P 2021-10-04 2021-10-04
US63/262,040 2021-10-04
PCT/CA2022/050038 WO2022150911A1 (en) 2021-01-13 2022-01-12 Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1

Publications (2)

Publication Number Publication Date
JP2024502178A JP2024502178A (ja) 2024-01-17
JP2024502178A5 true JP2024502178A5 (cg-RX-API-DMAC7.html) 2025-01-17

Family

ID=82446316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541702A Pending JP2024502178A (ja) 2021-01-13 2022-01-12 Sgk-1を阻害するためのピラゾロ[3,4-d]ピリミジン-6-イル-スルホンアミド誘導体

Country Status (7)

Country Link
US (1) US20240309005A1 (cg-RX-API-DMAC7.html)
EP (1) EP4277905A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024502178A (cg-RX-API-DMAC7.html)
KR (1) KR20230136622A (cg-RX-API-DMAC7.html)
CN (2) CN121517419A (cg-RX-API-DMAC7.html)
MX (1) MX2023008219A (cg-RX-API-DMAC7.html)
WO (1) WO2022150911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3261470A1 (en) * 2022-07-12 2024-01-18 Thryv Therapeutics Inc. N-[4-(4-[[2-(DIMETHYLAMINO)ETHYL]AMINO]-3-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)-2-FLUOROPHENYL]-2,5-DIFLOOROBENZENESULFONAMIDE SALTS AND THEIR CRYSTALLINE FORMS
WO2024015055A1 (en) * 2022-07-13 2024-01-18 Thryv Therapeutics Inc. Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer
KR102912267B1 (ko) * 2023-04-20 2026-01-15 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
EP4784582A1 (en) * 2023-09-27 2026-08-05 Bristol-Myers Squibb Company Piperidine substituted pyrazolopyrimidine derivatives as inhibitors of sgk1
WO2026107572A1 (en) * 2024-11-21 2026-05-28 Thryv Therapeutics Inc. Salts of n-[4-(4-[[2-(dimethylamino)ethyl]amino]-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-6-yl)-2-chlorophenyl]-2,5-difluorobenzenesulfonamide and crystalline forms thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5827849B2 (ja) * 2011-09-20 2015-12-02 サノフイ N−[4−(1H−ピラゾロ[3,4−b]ピラジン−6−イル)−フェニル]−スルホンアミド及び薬剤としてのその使用
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途
WO2015048531A1 (en) * 2013-09-26 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Inhibition of sgk1 in the treatment of heart conditions
CA3026983A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
KR102678781B1 (ko) * 2016-12-07 2024-06-27 오리모스 테라퓨틱스 씨오., 엘티디. Sgk 활성을 조절하기 위한 화합물 및 약학 조성물 및 이의 방법

Similar Documents

Publication Publication Date Title
JP2022121594A5 (cg-RX-API-DMAC7.html)
JP2021063088A5 (cg-RX-API-DMAC7.html)
JP2022533069A5 (cg-RX-API-DMAC7.html)
JP6087367B2 (ja) 三環式化合物、それらを含む組成物およびそれらの使用
JP2022543155A5 (cg-RX-API-DMAC7.html)
JP2007505933A5 (cg-RX-API-DMAC7.html)
JP2019530724A5 (cg-RX-API-DMAC7.html)
JP2007527919A5 (cg-RX-API-DMAC7.html)
JP2007504235A5 (cg-RX-API-DMAC7.html)
JP2009541225A5 (cg-RX-API-DMAC7.html)
JP2015508068A5 (cg-RX-API-DMAC7.html)
JP2023537271A5 (cg-RX-API-DMAC7.html)
KR20110013411A (ko) (f-19)-표지된 l-글루탐산 및 l-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법
JP2024545787A5 (cg-RX-API-DMAC7.html)
JP2023513793A5 (cg-RX-API-DMAC7.html)
JP2007505044A5 (cg-RX-API-DMAC7.html)
JP2023527961A5 (cg-RX-API-DMAC7.html)
JP2020511450A5 (cg-RX-API-DMAC7.html)
JP4852605B2 (ja) 放射線治療増強剤
JP2023524519A5 (cg-RX-API-DMAC7.html)
JP2022544803A5 (cg-RX-API-DMAC7.html)
FR2967671A1 (fr) Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
JP2022521474A5 (cg-RX-API-DMAC7.html)
JP2024517789A5 (cg-RX-API-DMAC7.html)
KR101920902B1 (ko) 심혈관 질환 조기진단 pet 조영용 화합물 및 그의 용도